Data_Sheet_3_Development and acceptability of a decision aid for anxiety disorder considering discontinuation of benzodiazepine anxiolytic.PDF

AimWe aimed to develop a decision aid (DA) for individuals with anxiety disorders who consider tapering benzodiazepine (BZD) anxiolytics, and if tapering, tapering BZD anxiolytics with or without cognitive behavioral therapy (CBT) for anxiety. We also assessed its acceptability among stakeholders.MethodsFirst, we conducted a literature review regarding anxiety disorders to determine treatment options. We cited the results of the systematic review and meta-analysis, which we conducted previously, to describe the related outcomes of two options: tapering BZD anxiolytics with CBT and tapering BZD anxiolytics without CBT. Second, we developed a DA prototype in accordance with the International Patient Decision Aid Standards. We carried out a mixed methods survey to assess the acceptability among stakeholders including those with anxiety disorders and healthcare providers.ResultsOur DA provided information such as explanation of anxiety disorders, options of tapering or not tapering BZD anxiolytics (if tapering, the options of tapering BZD anxiolytics with or without CBT) for anxiety disorder, benefits and risks of each option, and a worksheet for value clarification. For patients (n = 21), the DA appeared to be acceptable language (86%), adequate information (81%), and well-balanced presentation (86%). The developed DA was also acceptable for healthcare providers (n = 10).ConclusionWe successfully created a DA for individuals with anxiety disorders who consider tapering BZD anxiolytics, which was acceptable for both patients and healthcare providers. Our DA was designed to assist patients and healthcare providers to involve decision-making about whether to taper BZD anxiolytics or not.

本研究旨在为考虑减少苯二氮䓬类（BZD）抗焦虑药物的焦虑症患者开发决策辅助工具（DA），并评估其在包括焦虑症患者及医疗保健提供者在内的利益相关者中的可接受性。研究方法包括：首先，我们对焦虑症的相关文献进行了综述，以确定治疗方案；其次，我们引用了先前进行的系统综述和荟萃分析的结果，描述了两种方案的相关结果：即在认知行为疗法（CBT）辅助下减少BZD抗焦虑药物以及未辅助CBT的减少BZD抗焦虑药物。接着，我们根据国际患者决策辅助工具标准开发了DA原型。我们进行了一项混合方法调查，以评估包括焦虑症患者和医疗保健提供者在内的利益相关者的可接受性。研究结果：我们的DA提供了关于焦虑症的解释、减少或维持BZD抗焦虑药物（如减少，则包括是否在CBT辅助下减少）的选项、每种选项的益处和风险，以及价值澄清的工作表。对于患者（n=21），DA的可接受性表现在语言（86%）、信息充分性（81%）和平衡性（86%）方面。开发出的DA也受到医疗保健提供者（n=10）的认可。结论：我们成功地为考虑减少BZD抗焦虑药物的焦虑症患者创建了一个决策辅助工具，该工具既适合患者也适合医疗保健提供者，旨在协助患者和医疗保健提供者参与关于是否减少BZD抗焦虑药物的决策过程。